Related Experiment Video
Updated: Jul 23, 2026
Improving IV Insulin Administration in a Community Hospital
Published on: June 11, 2012
Efficacy of Control-IQ Technology in a General Endocrine Clinic
Chinenye O Usoh1, Catherine Price2, Crystal Paige Johnson2
1Division of Endocrinology, Diabetes and Metabolism, Wake Forest University School of Medicine, Winston-Salem, North Carolina; Endocrinology Service, W. G. (Bill) Hefner Veterans Affairs Medical Center, Salisbury, North Carolina.
Objective:
Recent advances in technology have allowed for the expanded use of hybrid closed-loop insulin pump therapy and automated insulin delivery systems for the management of diabetes mellitus. We assessed the outcomes of introducing Tandem t:slim X2 with the Control-IQ technology in a general endocrine clinic.
Methods:
Data from 66 adults with type 1 (n = 61) and type 2 (n = 5) diabetes mellitus were aggregated for analysis. Patients were either transitioned from traditional insulin pump therapy or multiple daily injection therapy to Tandem t:slim X2 with the Control-IQ technology from January 2020 to June 2021. The assessed clinical end points included changes in time below range, time above range, and time in target range. Changes in hemoglobin A1C before and after Control-IQ technology implementation were noted. The primary outcome was a change in time in target range with the Control-IQ technology.
Results:
There was a significant increase in time in target range when comparing pre- and post-Control-IQ technology (49.5% vs 63.3%, P < .0003) values. There was a reduction in time above range (46.8% vs 34.9%, P < .0013), a decrease in time below range (4.0% vs 1.7%, P = .017), and a decrease in hemoglobin A1C after transitioning to the Control-IQ technology (7.7% [61 mmol/mol] vs 7.1% [54 mmol/mol], P < .017). The patient dropout rate was low (7%).
Conclusion:
The Control-IQ technology system was effective in reducing hyperglycemia while increasing time in target range and decreasing hypoglycemia. This technology is a useful and effective addition to the growing number of automated insulin delivery systems. The clinical outcomes mirror the results found in the key adult pivotal trials.
